Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- ZYNE +2%, ONTX +1.7%
M&A news:
- DDC +4.6% (to explore, review, and evaluate a range of potential strategic alternatives)
- SEE +1.2% (to sell its Diversey Care division and the food hygiene and cleaning business within its Food Care division to Bain Capital Private Equity for approx. $3.2 bln)
- EVH +0.7% (Evolent Health / Advisory Board Company (ABCO) potential merger follow-up)
Select Hospital related names trading higher after news that ACHA has been pulled:
- CYH +2.2%, MOH +1.2%, HCA +1.6%, THC +1.8%, CNC +0.5%
Select metals/mining stocks trading higher:
- SBGL +5.2%, GFI +4.8%, AU +3.9%, AG +2.7%, SLW +2.7%, GOLD+2.6%, GDX +2.2%, ABX +2.1%, HL +2%, NEM +1.6%, SLV +1.4%,GLD +0.8%
Other news:
- HTGM +28% (continued strength)
- APOP +25.6% (announces that the first stem cell transplant procedure has been successfully performed using its ApoGraft technology in the Company's Phase I/II clinical trial in a blood cancer patient)
- DCTH +24.4% (announces special protocol assessment agreement with FDA for Pivotal Trial with Melphalan/HDS in Intrahepatic Cholangiocarcinoma; will initiate the pivotal trial this fall)
- PRTK +16.4% (Paratek Pharma and Allergan (AGN) announced that two Phase 3 trials of sarecycline for the treatment of moderate to severe acne met their 12 week primary efficacy endpoints)
- IPXL +13.5% (appoints Paul M. Bisaro as President and CEO effective immediately)
- WFT +8.3% (Schlumberger and Weatherford (WFT) to create OneStim joint venture - new company targets N Am 'unconventional resource development')
- MTNB +6.8% (reports 'positive' data from its Phase 1 single-ascending dose study of MAT2501 in healthy volunteers)
- BVX +5% (receives 510K clearance from the FDA for a new J-Plasma generator and handpiece that incorporate Cool-Coag technology)
- ZIOP +4.9% (announces the receipt of positive guidance from an End-of-Phase 2 meeting with the FDA for its lead gene therapy product candidate, Ad-RTS-hIL-12 plus orally administered veledimex)
- DSW +4.3% (will replace Texas Capital Bancshares in the S&P SmallCap 600)
- EXK +3.9% (reports its initial NI43-101 Mineral Resource Estimate and a PEA for its El Compas mine project located adjacent to the city of Zacatecas in Zacatecas state), URRE +3.4% (Uranium Resources unit enters into an Option Agreement to purchase a block of unpatented placer mining claims)
- MIK +2.9% (will replace WisdomTree Investments in the S&P MidCap 400)
- AUPH +2.9% ( reports Data from Open-Label AURION Study met primary objective)
- RT +1.6% (Leon Capital disclosed 9.5% active stake)
- AZN +1% (Tagrisso approved in China)
- EGRX +1% (announces that their 505(b)(2) NDA for Ryanodex for the treatment of exertional heat stroke has been accepted for filing and granted a priority review designation by the FDA)
Analyst comments:
- BPMX +14.3% (positive comments from H.C. Wainwright)
- SNAP +3% (initiated with a Buy at Citigroup; initiated with a Overweight at Morgan Stanley, among others)
- HIMX +1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)